Literature DB >> 21454717

Estimated GFR associates with cardiovascular risk factors independently of measured GFR.

Ulla Dorte Mathisen1, Toralf Melsom, Ole C Ingebretsen, Trond Jenssen, Inger Njølstad, Marit D Solbu, Ingrid Toft, Bjørn O Eriksen.   

Abstract

Estimation of the GFR (eGFR) using creatinine- or cystatin C-based equations is imperfect, especially when the true GFR is normal or near-normal. Modest reductions in eGFR from the normal range variably predict cardiovascular morbidity. If eGFR associates not only with measured GFR (mGFR) but also with cardiovascular risk factors, the effects of these non-GFR-related factors might bias the association between eGFR and outcome. To investigate these potential non-GFR-related associations between eGFR and cardiovascular risk factors, we measured GFR by iohexol clearance in a sample from the general population (age 50 to 62 years) without known cardiovascular disease, diabetes, or kidney disease. Even after adjustment for mGFR, eGFR associated with traditional cardiovascular risk factors in multiple regression analyses. More risk factors influenced cystatin C-based eGFR than creatinine-based eGFR, adjusted for mGFR, and some of the risk factors exhibited nonlinear effects in generalized additive models (P<0.05). These results suggest that eGFR, calculated using standard creatinine- or cystatin C-based equations, partially depends on factors other than the true GFR. Thus, estimates of cardiovascular risk associated with small changes in eGFR must be interpreted with caution.
Copyright © 2011 by the American Society of Nephrology

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21454717      PMCID: PMC3083314          DOI: 10.1681/ASN.2010050479

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  36 in total

1.  Clinical usefulness of cystatin C for the estimation of glomerular filtration rate in type 1 diabetes: reproducibility and accuracy compared with standard measures and iohexol clearance.

Authors:  G D Tan; A V Lewis; T J James; P Altmann; R P Taylor; J C Levy
Journal:  Diabetes Care       Date:  2002-11       Impact factor: 19.112

2.  Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency.

Authors:  B F Culleton; M G Larson; P W Wilson; J C Evans; P S Parfrey; D Levy
Journal:  Kidney Int       Date:  1999-12       Impact factor: 10.612

3.  Moderate renal insufficiency and the risk of cardiovascular mortality: results from the NHANES I.

Authors:  Amit X Garg; William F Clark; R Brian Haynes; Andrew A House
Journal:  Kidney Int       Date:  2002-04       Impact factor: 10.612

4.  Cystatin C concentration as a risk factor for heart failure in older adults.

Authors:  Mark J Sarnak; Ronit Katz; Catherine O Stehman-Breen; Linda F Fried; Nancy Swords Jenny; Bruce M Psaty; Anne B Newman; David Siscovick; Michael G Shlipak
Journal:  Ann Intern Med       Date:  2005-04-05       Impact factor: 25.391

5.  The association between atherosclerotic risk factors and renal function in the general population.

Authors:  Jacobien C Verhave; Hans L Hillege; Johannes G M Burgerhof; Ron T Gansevoort; Dick de Zeeuw; Paul E de Jong
Journal:  Kidney Int       Date:  2005-05       Impact factor: 10.612

6.  Effects of current smoking and smoking discontinuation on renal function and proteinuria in the general population.

Authors:  J M Halimi; B Giraudeau; S Vol; E Cacès; H Nivet; Y Lebranchu; J Tichet
Journal:  Kidney Int       Date:  2000-09       Impact factor: 10.612

7.  Plasma concentrations of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events: more than simply a marker of glomerular filtration rate.

Authors:  Wolfgang Koenig; Dorothee Twardella; Hermann Brenner; Dietrich Rothenbacher
Journal:  Clin Chem       Date:  2004-11-24       Impact factor: 8.327

8.  Smoking is related to albuminuria and abnormal renal function in nondiabetic persons.

Authors:  S J Pinto-Sietsma; J Mulder; W M Janssen; H L Hillege; D de Zeeuw; P E de Jong
Journal:  Ann Intern Med       Date:  2000-10-17       Impact factor: 25.391

9.  Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement.

Authors:  Eric L Knight; Jacobien C Verhave; Donna Spiegelman; Hans L Hillege; Dick de Zeeuw; Gary C Curhan; Paul E de Jong
Journal:  Kidney Int       Date:  2004-04       Impact factor: 10.612

10.  Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community.

Authors:  Guruprasad Manjunath; Hocine Tighiouart; Hassan Ibrahim; Bonnie MacLeod; Deeb N Salem; John L Griffith; Josef Coresh; Andrew S Levey; Mark J Sarnak
Journal:  J Am Coll Cardiol       Date:  2003-01-01       Impact factor: 24.094

View more
  45 in total

1.  Filtration markers may have prognostic value independent of glomerular filtration rate.

Authors:  Navdeep Tangri; Lesley A Inker; Hocine Tighiouart; Eric Sorensen; Vandana Menon; Gerald Beck; Michael Shlipak; Josef Coresh; Andrew S Levey; Mark J Sarnak
Journal:  J Am Soc Nephrol       Date:  2011-12-15       Impact factor: 10.121

2.  Chronic kidney disease: Endogenous filtration markers--is it time to move beyond eGFR?

Authors:  Andrew D Rule; Hisham Elsherbiny
Journal:  Nat Rev Nephrol       Date:  2011-11-29       Impact factor: 28.314

3.  Serum cystatin C as a predictor for cardiovascular events in end-stage renal disease patients at the initiation of dialysis.

Authors:  Min Ji Shin; Sang Heon Song; Ihm Soo Kwak; Soo Bong Lee; Dong Won Lee; Eun Young Seong; Il Young Kim; Harin Rhee; Naria Lee
Journal:  Clin Exp Nephrol       Date:  2012-01-26       Impact factor: 2.801

4.  GFR estimating equations: getting closer to the truth?

Authors:  Andrew D Rule; Richard J Glassock
Journal:  Clin J Am Soc Nephrol       Date:  2013-05-23       Impact factor: 8.237

5.  GFR in Healthy Aging: an Individual Participant Data Meta-Analysis of Iohexol Clearance in European Population-Based Cohorts.

Authors:  Bjørn O Eriksen; Runolfur Palsson; Natalie Ebert; Toralf Melsom; Markus van der Giet; Vilmundur Gudnason; Olafur S Indridason; Lesley A Inker; Trond G Jenssen; Andrew S Levey; Marit D Solbu; Hocine Tighiouart; Elke Schaeffner
Journal:  J Am Soc Nephrol       Date:  2020-06-04       Impact factor: 10.121

6.  Chronic kidney disease: Cystatin-C-based eGFR: what is it telling us?

Authors:  Kristen L Jablonski; Michel Chonchol
Journal:  Nat Rev Nephrol       Date:  2013-04-16       Impact factor: 28.314

7.  Mediation analysis of aortic stiffness and renal microvascular function.

Authors:  Todd Woodard; Sigurdur Sigurdsson; John D Gotal; Alyssa A Torjesen; Lesley A Inker; Thor Aspelund; Gudny Eiriksdottir; Vilmundur Gudnason; Tamara B Harris; Lenore J Launer; Andrew S Levey; Gary F Mitchell
Journal:  J Am Soc Nephrol       Date:  2014-10-07       Impact factor: 10.121

8.  Non-GFR Determinants of Low-Molecular-Weight Serum Protein Filtration Markers in CKD.

Authors:  Xun Liu; Meredith C Foster; Hocine Tighiouart; Amanda H Anderson; Gerald J Beck; Gabriel Contreras; Josef Coresh; John H Eckfeldt; Harold I Feldman; Tom Greene; L Lee Hamm; Jiang He; Edward Horwitz; Julia Lewis; Ana C Ricardo; Haochang Shou; Raymond R Townsend; Matthew R Weir; Lesley A Inker; Andrew S Levey
Journal:  Am J Kidney Dis       Date:  2016-09-20       Impact factor: 8.860

9.  Creatinine-Based and Cystatin C-Based GFR Estimating Equations and Their Non-GFR Determinants in Kidney Transplant Recipients.

Authors:  Mira T Keddis; Hatem Amer; Nikolay Voskoboev; Walter K Kremers; Andrew D Rule; John C Lieske
Journal:  Clin J Am Soc Nephrol       Date:  2016-06-23       Impact factor: 8.237

10.  Physical exercise, fasting glucose, and renal hyperfiltration in the general population: the Renal Iohexol Clearance Survey in Tromsø 6 (RENIS-T6).

Authors:  Toralf Melsom; Ulla Dorte Mathisen; Britt-Ann Winther Eilertsen; Ole C Ingebretsen; Trond Jenssen; Inger Njølstad; Marit D Solbu; Ingrid Toft; Bjørn O Eriksen
Journal:  Clin J Am Soc Nephrol       Date:  2012-08-23       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.